Morepen Laboratories Limited

Morepen Laboratories Limited

Morepen Laboratories Limited has received a favorable judgment from the Hon'ble High Court of Himachal Pradesh at Shimla, quashing a Show Cause Notice (SCN) issued by the Office of the Commissioner, Central GST & Central Excise Commissionerate, Shimla, seeking recovery of ₹117,94,03,452/- towards excess GST refund, along with applicable interest and penalty.

Morepen Laboratories Limited

Morepen Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of unaudited consolidated and standalone financial results for the quarter and half year ended on 30th September 2026.

Morepen Laboratories Limited

Morepen Laboratories Limited has submitted its first Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration for Sitagliptin Tablets USP in three strengths, marking a milestone in its integrated CDMO capabilities.

Morepen Laboratories Limited

Morepen Laboratories Limited has announced the voting results and scrutinizer report of its 41st Annual General Meeting (AGM) held on September 26, 2026, through video conferencing.

Morepen Laboratories Limited

Morepen Laboratories Limited has informed the Exchange regarding Proceedings of 41st Annual General Meeting held on September 26, 2026. The meeting was held through Video Conferencing/ Other Audio-Visual Means and the requisite quorum was present. The notice of the meeting dated 4th August 2026 along with Directors' Report and the Auditors' Report for the financial year ended 31st March 2026 were taken as read. The following items of business were transacted at the meeting: consideration and adoption of the audited financial statements, declaration of the final dividend, appointment of a Director, ratification of remuneration of Cost Auditors, elevation and change in designation of Mr. Sanjay Suri, re-appointment of Mr. Sushil Suri, and extension of approved timeline for hiving off Medical Devices Business.

Morepen Laboratories Limited

Morepen Laboratories Limited has received an ESG rating of 'CRISIL ESG 60' from Crisil ESG Ratings & Analytics Limited, indicating an 'Adequate' rating category.

Morepen Laboratories Limited

Morepen Laboratories Limited has completed the first phase of its manufacturing capacity expansion program ahead of schedule, increasing its installed reactor capacity for API and CDMO from 535 KL to 614 KL.

Morepen Laboratories Limited

Morepen Laboratories Limited has published a newspaper notice for the completion of dispatch of the notice of its 41st Annual General Meeting and the Annual Report for the financial year 2025-26.

Morepen Laboratories Limited

Morepen Laboratories Limited has informed the Exchange regarding the dispatch of letters to members whose email IDs are not registered with the company, comprising the weblink to access the Annual Report for the financial year 2025-26. The company has also announced the 41st Annual General Meeting (AGM) to be held on September 26, 2026, and proposed a final dividend of ₹ 0.20 per equity share.

Morepen Laboratories Limited

Morepen Laboratories Limited has informed the Exchange about Shareholders meeting, notice of 41st Annual General Meeting, record date and book closure.

Morepen Laboratories Limited

Morepen Laboratories Limited has published a newspaper advertisement regarding its 41st Annual General Meeting, dividend, and record date.

Morepen Laboratories Limited

Morepen Laboratories Limited has informed the Exchange about allotment of equity shares by Morepen RX Limited, a wholly owned subsidiary, to the company. The allotment of 2,00,00,000 equity shares at par, aggregating to Rs. 20,00,00,000, has strengthened the company's shareholding in MRX to 2,70,82,356 equity shares.

Morepen Laboratories Limited

Morepen Laboratories Limited has published its un-audited standalone and consolidated financial results for the quarter ended June 30, 2026, in accordance with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Morepen Laboratories Limited

Morepen Laboratories Limited has submitted a Monitoring Agency Report for the quarter ended June 30, 2026, as per SEBI Regulations and Monitoring Agency Agreement dated August 01, 2024. The report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue.

Morepen Laboratories Limited

Morepen Laboratories Limited has informed the Exchange about Intimation of 41st Annual General Meeting scheduled to be held on September 26, 2026, and the Board of Directors have considered and approved several matters, including un-audited standalone & consolidated financial results for the quarter ended June 30, 2026, and the re-appointment of Mr. Sushil Suri as the Chairman & Managing Director of the company.

Morepen Laboratories Limited

Morepen Laboratories Limited has informed the Exchange regarding the re-appointment of Mr. Sushil Suri as Chairman & Managing Director of the company, effective from October 20, 2026. The company has also announced its un-audited standalone & consolidated financial results for the quarter ended June 30, 2026, and has set a record date for the final dividend for the financial year ended March 31, 2026. Additionally, the company has announced the extension of the approved timeline for hiving off its Medical Devices Business into a subsidiary company, Morepen Medipath Limited, and has scheduled its 41st Annual General Meeting for September 26, 2026.

Morepen Laboratories Limited

Morepen Laboratories Limited has informed the Exchange that Record date for the purpose of Final Dividend is 19-Sep-2026. The company has also approved the financial results for the quarter ended 30th June 2026, and has announced the re-appointment of Mr. Sushil Suri as the Chairman & Managing Director of the company.

Morepen Laboratories Limited

Morepen Laboratories Limited has announced its financial results for Q1 FY27, reporting its highest-ever quarterly revenue and earnings, supported by better operating leverage, improved performance on API front, strong export growth and full scale commercialization of CDMO mandate.

Morepen Laboratories Limited

Morepen Laboratories Limited has informed the Exchange about Investor Presentation

Morepen Laboratories Limited

Morepen Laboratories Limited has announced its un-audited standalone and consolidated financial results for the quarter ended June 30, 2026, and has also approved the re-appointment of its Chairman and Managing Director, Sushil Suri, for a further period of three years. The company has also fixed a record date for the final dividend for the financial year ended March 31, 2026, and has scheduled its 41st Annual General Meeting for September 26, 2026.